Compare CIVB & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIVB | IPSC |
|---|---|---|
| Founded | 1884 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.9M | 413.0M |
| IPO Year | 2012 | 2021 |
| Metric | CIVB | IPSC |
|---|---|---|
| Price | $24.92 | $2.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $26.60 | $4.25 |
| AVG Volume (30 Days) | 73.3K | ★ 899.0K |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | 31.34 | ★ 91.30 |
| EPS | ★ 2.64 | N/A |
| Revenue | $19,023,000.00 | ★ $109,164,000.00 |
| Revenue This Year | $14.88 | N/A |
| Revenue Next Year | $5.99 | N/A |
| P/E Ratio | $9.45 | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $18.95 | $0.44 |
| 52 Week High | $25.83 | $2.97 |
| Indicator | CIVB | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 59.31 | 49.62 |
| Support Level | $21.39 | $2.15 |
| Resistance Level | N/A | $2.67 |
| Average True Range (ATR) | 0.74 | 0.12 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 62.67 | 46.67 |
Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agricultural, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. The majority of its revenues are derived from the interest and fees gained on loans.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.